Marubi(SH:603983) Sou Hu Cai Jing·2025-11-26 17:05Core Viewpoint - The company, Marubi Biotechnology Co., Ltd., is planning a secondary listing in Hong Kong to enhance its capital strength and overseas financing capabilities, despite facing cash flow pressures and regulatory scrutiny [1][2][9]. Financial Performance - Marubi reported total revenue of 686 million yuan for Q3 2025, a year-on-year increase of 14.28%, and total revenue of 2.45 billion yuan for the first three quarters, up 25.51% year-on-year [1]. - The net profit attributable to shareholders for Q3 was 69.48 million yuan, a year-on-year increase of 11.59%, while the first three quarters saw a net profit of 240 million yuan, up 2.13% year-on-year [1][4]. - However, the company's non-recurring net profit fell by nearly 20% in Q3 and 5.42% in the first three quarters, indicating a potential decline in the contribution of core business to profits [4][5]. Cost Structure - Sales expenses for the first three quarters reached 1.41 billion yuan, a 32% increase year-on-year, accounting for 57.6% of total revenue [5]. - The company's gross margin remained high at around 75%, which is above the industry average for domestic beauty brands [4]. Cash Flow and Investments - The net increase in cash and cash equivalents turned negative, dropping from 270 million yuan in the previous year to -390 million yuan this year, with total cash funds decreasing from 2.03 billion yuan to 1.59 billion yuan [9]. - Fixed asset investments nearly doubled, rising from 4.76 billion yuan to 9.97 billion yuan, indicating significant property acquisitions that have impacted cash flow [9]. Dividend Policy - Despite cash flow pressures, Marubi announced a dividend of 100 million yuan, with a per-share payout of 0.25 yuan, primarily benefiting the founding couple who hold over 80% of the shares [10][11]. - The high dividend payout raises questions about the company's financial strategy, especially in light of its upcoming secondary listing [10][11]. Regulatory Issues - The company received a warning from the China Securities Regulatory Commission for irregular financial accounting, including issues with revenue recognition and improper management of raised funds [16]. - These regulatory concerns may affect investor perception and valuation during the upcoming listing [17].